Alps Group Inc (ALPS)
NASDAQ: ALPS · Real-Time Price · USD
0.9000
-0.0150 (-1.64%)
At close: Apr 24, 2026, 4:00 PM EDT
0.9310
+0.0310 (3.44%)
After-hours: Apr 24, 2026, 4:29 PM EDT
Alps Group Market Cap
Alps Group has a market cap or net worth of $149.76 million as of April 24, 2026. Its market cap has increased by 66.57% in one year.
Market Cap
149.76M
Enterprise Value
149.90M
1-Year Change
66.57%
Ranking
Category
Stock Price
$0.90
Market Cap Chart
Since December 23, 2021, Alps Group's market cap has increased from $143.00M to $149.76M, an increase of 4.73%. That is a compound annual growth rate of 1.07%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 24, 2026 | 149.76M | 3.52% |
| Dec 31, 2025 | 144.67M | 230.19% |
| Dec 30, 2024 | 43.81M | -50.64% |
| Dec 29, 2023 | 88.76M | -41.77% |
| Dec 30, 2022 | 152.44M | 6.93% |
| Dec 30, 2021 | 142.56M | -0.30% |
| Dec 23, 2021 | 143.00M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| ProQR Therapeutics | 163.31M |
| Spero Therapeutics | 158.62M |
| AN2 Therapeutics | 156.94M |
| Molecular Partners AG | 155.64M |
| Oramed Pharmaceuticals | 155.52M |
| Humacyte | 155.41M |
| Fate Therapeutics | 154.63M |
| Galectin Therapeutics | 153.38M |